good presentation. I am interested in the competition- sparsentan - and the impact of its pending approval (likely early 2023). If sparsanten targets both modes of action, why do we need DXB? if this competitor gets approved, how does it affect our orphan drug status?
good presentation. I am interested in the competition-...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
0.025(7.46%) |
Mkt cap ! $197.8M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.3¢ | 33.5¢ | $3.801M | 10.73M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 378856 | 6 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
36.0¢ |
Change
0.025 ( 7.33 %) |
||||
| Open | High | Low | Volume | ||
| 33.5¢ | 36.5¢ | 33.5¢ | 5557634 | ||
| Last updated 15.58pm 03/05/2024 ? | |||||
| DXB (ASX) Chart |